Upcoming · By Invitation

International Translational Oncology Exchange

Boston · May 13, 202614:00 – 16:00 ET
Learn more →
←Back to Expert Scholars
research / researchCancer Immunoprevention & Vaccines

Olivera Finn

奥利维拉·芬恩

PhD

🏢University of Pittsburgh School of Medicine(匹兹堡大学医学院)🌐USA

Distinguished Professor, Department of Immunology; Co-Director, Cancer Immunology Program, UPMC Hillman Cancer Center免疫学系杰出教授；UPMC希尔曼癌症中心癌症免疫学项目联合主任

78
h-index
2
Key Papers
4
Awards
2
Key Contributions

👥Biography 个人简介

Pioneer of cancer immunoprevention. Developed MUC1-based preventive vaccines targeting high-risk individuals with pre-malignant conditions such as colorectal adenomas. Ran the first phase I clinical trial of a cancer preventive vaccine in healthy high-risk individuals. Past president of the American Association for Cancer Research (AACR).

Share:

🧪Research Fields 研究领域

MUC1 Cancer Preventive VaccinesMUC1癌症预防性疫苗
Cancer Immunoprevention癌症免疫预防
Tumor Antigen Immunology肿瘤抗原免疫学
Preventive Vaccine Clinical Trials预防性疫苗临床试验
Cancer Immune Surveillance癌症免疫监视

🎓Key Contributions 主要贡献

MUC1 Preventive Vaccine Development

Developed and conducted the first clinical trial of a prophylactic MUC1 vaccine in individuals with colorectal adenomas, demonstrating immune responses correlated with reduced adenoma recurrence.

Cancer Immunoprevention Framework

Established the theoretical and experimental basis for cancer immunoprevention, arguing that immune responses to tumor antigens in pre-malignant stages could prevent cancer initiation and progression.

Representative Works 代表性著作

[1]

Immunological ignorance of vimentin is overcome by inflammatory conditions to induce epitope spreading and progressive multiple sclerosis

Journal of Experimental Medicine (2016)

Demonstrated mechanisms of immune tolerance breakdown relevant to cancer immunoprevention strategies.

[2]

Phase I clinical trial of a MUC1 cancer vaccine in patients with high risk for colorectal cancer

Cancer Prevention Research (2011)

First preventive cancer vaccine clinical trial in healthy high-risk individuals, showing safety and immunogenicity of MUC1 vaccination.

🏆Awards & Recognition 奖项与荣誉

🏆AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research (2021)
🏆William B. Coley Award for Distinguished Research in Basic and Tumor Immunology
🏆American Cancer Society Research Professorship
🏆AACR President (2009-2010)

📄Data Sources 数据来源

Institution

Last updated: 2026-01-15 | All information from publicly available academic sources

Related Experts 相关专家

Faisal Mahmood

Brigham and Women's Hospital; Harvard Medical School

Computational Pathology — Deep Learning for Whole-Slide Image Analysis and Tumor Microenvironment CharacterizationFoundation Models for Pathology — CONCH and TITAN Vision-Language Models for Oncology

Kun-Hsing Yu

Harvard Medical School; Brigham and Women's Hospital

Multimodal Oncology AI — Integrating Pathology Images, Genomics, Proteomics, and Clinical RecordsAI Pathology-Genomics Integration — Predicting Molecular Alterations from Histomorphology

Ziad Obermeyer

University of California, Berkeley; UC San Francisco

Algorithmic Bias in Healthcare AI — Racial Disparities in Predictive Risk ScoresPredictive Models for Cancer and Critical Illness — Machine Learning in Clinical Practice

Andrew H. Beck

PathAI; Harvard Medical School (formerly)

PathAI — Founding and Scientific Direction of AI-Powered Pathology PlatformDeep Learning for Pathology Biomarker Discovery — TILs, Fibrosis, and Tumor Architecture

关注 奥利维拉·芬恩 的研究动态

Follow Olivera Finn's research updates

留下邮箱，当我们发布与 Olivera Finn（University of Pittsburgh School of Medicine）相关的新研究或访谈时，我们会通知你。

我们不会泄露你的信息，也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment

Browse All ExpertsRead Research Insights